BioNxt Solutions Inc · CSE:BNXT
BioNxt Solutions — Investor Presentation (November 2024)
23 slides from BioNxt Solutions's investor presentation, November 2024
Slide 1: Next-Gen Drug Delivery for Neurodegenerative Health
Next-Gen Drug Delivery for Neurodegenerative Health CORPORATE PRESENTATION NOVEMBER 2024
Slide 2: Forward looking statements
Forward looking statements This presentation has been prepared by BioNxt Solutions Inc. (the These statements are based on management’s current beliefs and “Company”) for informational purposes only and does not constitute assumptions, but are not guarantees of future performance. Forward- an offer
Slide 3: Our Vision / Our Mission
Our Vision “Leading the revolution in next-gen drug delivery systems and improving the quality of life for millions of patients worldwide.” HUGH ROGERS CO-FOUNDER, Our Mission CEO & DIRECTOR We innovate drug delivery technologies for faster, more effective neurodegenerative treatments. Our expertise
Slide 4: Leaders in thin-film drug delivery
WHO WE ARE Leaders in thin-film drug delivery BioNxt Solutions Inc., a Canadian bioscience pioneer with R&D and manufacturing in Germany, specializes in thin-film (sublingual) and skin patch (transdermal) drug delivery for neurological and autoimmune diseases, enhancing patient compliance and bioava
Slide 5: What is an ODF (Oral Dissolvable Film)?
What is an ODF (Oral Dissolvable Film)? How Does Advantages It Work? for Patients Rapid Dissolution Enhanced Compliance Placed on or under Especially beneficial the tongue, the film for neurological conditions disintegrates within where swallowing difficulties seconds. are common. Efficient Absorpti
Slide 6: ODF Advantages Compared to other Dosage Forms
ODF Advantages Compared to other Dosage Forms Bypasses the Easy to apply Easy application to Well defined No risk of suffocation Improved gastrointestinal tract and does not require patients with dosage form and chocking stability and thus increasing water swallowing problems bioavailability Offers
Slide 7: Strong Pipeline - Still More to Come
Strong Pipeline - Still More to Come Pilot Extended Global Market Global Market Pre-Clinical IMPD Pharmacokinetic Pharmacokinetic Regulatory Therapeutic area Development Study in healthy Study in healthy Efficacy study USD Billions USD Billions Studies preparation Approval volunteers volunteers toda
Slide 8: Cladribine for Multiple Sclerosis (MS)
Cladribine for Multiple Sclerosis (MS) About Multiple Sclerosis (MS) MS is a chronic neurological disease affecting 2.9 million people globally, with 85% of cases as Relapsing-Remitting MS. Current treatments only manage symptoms and reduce relapses. Cladribine’s Impact BioNxt’s sublingual Cladribin
Slide 9: Lead Product BNT23001: ODF Cladribine for Multiple Sclerosis (MS)
Lead Product BNT23001: ODF Cladribine for Multiple Sclerosis (MS) Product Overview Market Analysis Next Steps High Efficacy Formulation Current Sales Human Cladribine is proven in over 75 Cladribine in a flexible, Mavenclad (Cladribine tablet) Bioequivalence Study fast-dissolving ODF for reached €1
Slide 10: Product BNT23001: ODF Cladribine for Myasthenia Gravis (MG)
Product BNT23001: ODF Cladribine for Myasthenia Gravis (MG) Product Overview Market Analysis Next Steps Formulation Growth Potential Clinical Trials Sublingual ODF thin film designed The MG treatment market is Preparing to initiate trials to for rapid lymphatic absorption. projected to double by 203
Slide 11: Product BNT24002: Sublingual Formulation for Lupus Nephritis (LN)
Product BNT24002: Sublingual Formulation for Lupus Nephritis (LN) Product Overview Market Analysis Next Steps Formulation Unique Benefits Growth Potential To complete formulation Sublingual thin film will Lupus nephritis is considered an The LM treatment market development and initiate be designed f
Slide 12: Product BNT24003: Sublingual Formulation for Reumatoid Arthritis (RA)
Product BNT24003: Sublingual Formulation for Reumatoid Arthritis (RA) Product Overview Market Next Steps Analysis The sublingual thin film Benefits Growth Potential To complete formulation for BNT24003 is designed The RA treatment development and initiate 01 Rheumatoid arthritis (RA) affects 1.3 mil
Slide 13: Product BNT24004: Sublingual Formulation for Longevity and Anti-Aging
Product BNT24004: Sublingual Formulation for Longevity and Anti-Aging Product Overview Market Next Steps Analysis Formulation Growth Potential To complete formulation Sublingual formulation of most promising drug-candidate for anti- The anti-aging drug development and initiate Pre- aging and longevi
Slide 14: Market Opportunity
Market Opportunity Neurodegenerative Autoimmune Diseases (Focus: Disorders (Focus: Multiple Sclerosis) Myasthenia Gravis) Global Market Prevalence $28 billion in 2021, projected ~14-40 per 100,000 people to reach $41 billion by 2033 in the U.S.; rising due to better (CAGR: 3.8%). diagnosis and aware
Slide 15: Pharmaceutical Drug Delivery Market
Pharmaceutical Drug Delivery Market Market 2024 Market Size Focus Segment Potential USD 1.97 trillion, projected Rapidly growing demand for to reach USD 3.18 trillion by innovative drug delivery, including 2034 (CAGR: 4.9%) thin-film technologies BioNxt’s Regional Opportunity Differentiation Strateg
Slide 16: Protecting Innovation: Patent & IP Framework
Protecting Innovation: Patent & IP Framework • Positive International Examination • Continuation based on Report (ISR) received from the European EP22179104, priority date Patent Office Q3 2024 transferred from EP application • Broad coverage for all sublingual drug • Further amendments / products w
Slide 17: Company Overview
Company Key Differentiators Core Expertise Overview Strategic IP and Advanced Drug Delivery Patent Portfolio Specialized in thin-film ODF (sublingual) and transdermal (skin Strong patent protection for sublingual chemotherapy drug patch) drug formulations for increased bioavailability and patient co
Slide 18: Investment Highlights
Investment Highlights Expanding Markets Unmet Needs We're a publicly The MS and MG markets are BioNxt’s ODF technology traded company projected to reach $41B and improves patient compliance, $6.7B by 2033 and 2032, especially for those with Canadian Security Exchange: BNXT respectively. swallowing d
Slide 19: Strong leadership with extensive experience across all relevant fields
Strong leadership with extensive experience across all relevant fields HUGH DR. OLEKSANDR PROF. DR. RAIMAR ROGERS ZABUDKIN LÖBENBERG CO-FOUNDER, IRECTOR OF BUSINESS D CO-FOUNDER CEO & DIRECTOR DEVELOPMENT & DIRECTOR DR.FLORIAN WOLFGANG DR. WOLFGANG A.SAHR PROBST W AGNER HEAD OF PROJECT O-FOUNDE
Slide 20: Research & Technology Partners
Research & Technology Partners Conscio Group provides scientific Gen-Plus is a German company Quinta-Analytica is a European The University of Alberta and analytical services to help specializing in pharmaceutical Contract Research Organization conducts cutting-edge research clients achieve performa
Slide 21: Why BioNxt continues to show growth and excellent performance
Why BioNxt continues to show growth and excellent performance Cutting-Edge Drug Flagship Product: Sublingual Strong Experienced Delivery Solutions ODF Cladribine for MS Intellectual Property Leadership and R&D BioNxt specializes in innovative A novel thin-film Cladribine ODF for Broad, patent-protec
Slide 22: Thank you!
Thank you! Investor & Media Contact: Hugh Rogers (CEO) bionxt.com hrogers@bionxt.com linkedin.com/company/bionxt-solutions +1 604 250 6162 instagram.com/bionxt Next-gen drug delivery BioNxt Solutions Inc. 22
Slide 23: References
References 1. Global Market Sizes & Projections: Multiple Sclerosis Market: The global multiple sclerosis therapeutic market was valued at USD 25.94 billion in 2023 and is projected to grow. Source: www.grandviewresearch.com/industry-analysis/multiple-sclerosis-therapeutics-market Myasthenia Gravis
BioNxt Solutions — Investor Presentation (November 2024) on 6ix